

The Annual General Pediatric Review & Self Assessment



# STATISTICS & EBM

**Rani S. Gereige, MD, MPH, FAAP**

Executive Director of Medical Education &  
Designated Institutional Official (DIO)

DEI Lead

Nicklaus Children's Hospital

Clinical Professor of Pediatrics

Florida International University College of Medicine

Miami, Florida

[Rani.Gereige@Nicklaushealth.org](mailto:Rani.Gereige@Nicklaushealth.org)





## The Annual General Pediatric Review & Self Assessment

# Disclosure of Relevant Relationship

Dr. Gereige has not had (in the past 24 months) any relevant conflicts of interest or relevant financial relationship with the manufacturers of products or services that will be discussed in this CME activity or in his presentation.

Dr. Gereige will support this presentation and clinical recommendations with the “best available evidence” from medical literature.

Dr. Gereige does not intend to discuss an unapproved/investigative use of a commercial product/device in this presentation.

# PREP Self-Assessment Content Specs (2013-2017)

*What You Need to Know?*



# Research & Statistics

## A. Study design: Understand the following:

1. Validity hierarchy for study design and study type
2. The uses and limitations of:
  - ✓ Randomized clinical trials
  - ✓ Controlled clinical trials
  - ✓ Cohort studies
  - ✓ Case-control studies
  - ✓ Cross-sectional and longitudinal studies
  - ✓ Systematic review and meta-analysis
  - ✓ Descriptive epidemiologic studies
  - ✓ Case reports/series and anecdotal evidence
3. How **sample size** affects the **power** of a study
4. How sample size may limit the ability to detect adverse events
5. Identify the **study design** most likely to yield valid information about:
  - ✓ The accuracy of a **diagnostic test**
  - ✓ The **benefits and/or harms** of an intervention
  - ✓ The **prognosis** of a condition

## B. Data analysis

1. Understand:
  - ✓ **Validity** and how it might be compromised
  - ✓ **Reliability** and how it might be compromised
  - ✓ **Bias** and how it might distort the estimate of the association between exposure and outcome
  - ✓ **Confounding** and how to control for it in a study
  - ✓ **Generalizability** and how it relates to validity
  - ✓ The concept of **intention-to-treat analysis** to maintain the power of a study
  - ✓ The concept of **number-needed-to-treat** when utilized to describe therapeutic interventions
2. Distinguish between **type I and type II statistical errors**
3. Assess how the **data source** (eg, diaries, billing data, discharge diagnostic code) may affect study results

Ref: AAP - 2013-2017 PREP SA



# Research & Statistics (Cont'ed)

## C. Reading and interpreting results

1. Understand the following:
  - ✓ Prevalence and incidence
  - ✓ Pre-test and post-test probability
  - ✓ Positive and negative predictive values
  - ✓ Sensitivity and specificity and how to apply them to test results
  - ✓ Standard deviation in the interpretation of results
  - ✓ Standard error in the interpretation of results
  - ✓ Confidence interval in the interpretation of results
  - ✓ Likelihood ratio and when it might be useful to reach a diagnosis
  - ✓ Relative risk analysis and odds ratio
2. Distinguish **statistical significance** from clinical importance
3. Given the need for specific clinical information, identify a clear, structured, searchable **clinical question**



Ref: AAP - 2013-2017 PREP SA



# Outline for Today's Lecture

- **Data Analysis**

- Accuracy (Validity) & Precision (Reliability)
- Bias & Confounding: Ways to minimize Bias and Confounding
- Relative Risk (RR); Absolute Risk Reduction (ARR); Relative Risk Reduction (RRR); & Number Needed to Treat (NNT)
- Types of Data
- Type I & Type II Errors
- P-Value, Power, Effect Size

- **Research/ Study Design**

- Types of Studies: Observational Vs Experimental (Strengths & Limitations)
- Hierarchy of Research Design

- **Reading & Interpreting Results (EBM)**

- Clinical Questions
- Therapy Studies (NNT), Intention-to-Treat
- Harm/Association (NNH)
- Diagnostic Tests (Sens, Spec, PPV, NPV, LRs, Pre & Post-Test Probability)
- Prognosis



bar inference  
 analysis **sample** inferences  
 precision research  
**population** make dichotomous  
 ordinal **biostatistical** variables estimate  
 outcomes continuous  
 classified generalizable endpoints  
 subset histogram prevalence question  
 range categorical random  
 chart analyses

# BASIC BIOSTATISTICS



Data

Quantitative  
(Numerical)

Continuous  
variables

Discrete  
variables

Qualitative  
(Categorical)

Nominal  
variables

Ordinal  
Variables



Not all variables  
expressed in  
numbers are  
quantitative type  
of data





\* Expressed in  
**numbers**

## Quantitative (Numerical)

### Continuous Variables

- **NUMERICAL** data
- Can take any value in the range or scale of measure
- e.g. Age (2, 2.5, 3.5 years); Weight, Height, BP

- Data consists of  
**COUNTS**

- Usually integer (no decimals)
- e.g. *No. of children; No. of admissions; No. of cigarettes smoked*

### Discrete Variables

Data

Quantitative  
(Numerical)

Continuous  
variables

Discrete  
variables

Qualitative  
(Categorical)

Nominal  
variables

Ordinal  
Variables



Not all variables expressed in numbers are quantitative type of data



- \* Expressed in terms of **natural language description**
- \* Can be named
- \* Represent **Categories/ groups**
- \* Cannot be measured but counted
- \* e.g. *Gender (M, F); Bld Group; Pain Severity (Mild, Mod, Severe); or Likert Scale*

## Qualitative (Categorical)

## Nominal Variables

- **NO order/ No Ranking**
- **Dichotomous** (M; F or dead/alive) or **Non-dichotomous** (Bld Grp, Ethnicity)

**Nominal Variable**  
No one category has higher value than the others

- **Ordered/ Ranked** categories (e.g. *Cancer Stage, Pain Severity, Likert Scale*) Versus discrete data
- Difference between ranks is not a numeric value

## Ordinal Variables (Ranked)

# Descriptive Statistics – Characteristics include:

## Central Tendency


- Estimate of “center” of a distribution of values

## Distribution of Data

- Normal (parametric distribution)
- Non-normal (non-parametric)
- Presented as frequency distribution

## Dispersion/ Variation

- Spread of values around the central tendency



# Measures of Central Tendency

*Estimate of center of distribution of values. Three types of estimates*

## Mean

- **Average** of **all** values (uses ALL values in a sample)
- **Most commonly used** measure of central tendency
- Used in many statistical equations
- Influenced by extreme values (Skewed distribution)

## Median

- **Exact middle** of a set of “ordered” values
- **Less sensitive to extreme values**
- **Better measure of a central tendency in highly skewed distributions** eg. Family income
- Should be accompanied by inter-quartile range (IQR)
  - eg. Family income: median\$ 25,000 (25-75 centile range 15,000-45,000)

## Mode


- **most frequently occurring** value in a set
- It is only measure of central tendency for **nominal data**
- Has a high sample fluctuations
- A sample may have more than one mode (multimodal distribution)
- Eg: *O +ve is the most frequent blood group in US*

# Distribution of Data





**HINT: Mean to the side of the tail to the median**

- Normal distribution:
  - Mean=median=mode
- Skewed **to left** distribution:
  - Mean<median
    - Eg: *birth weight in an NICU*
- Skewed **to right** distribution
  - Mean>median
    - Eg: *income*




# Skewed Distribution



# Measures of Variation/ Dispersion/ Spread

- Inter-quartile range
  - Around **Median**
- Variance
- Standard Deviation = the positive square root of the Variance
  - Around **Mean**
  - 95% sample data with 1.96 SD on each side of the mean
- Range = Largest value – Smallest value





# Confidence Intervals

---

- An estimate of a population parameter
- Stated as a range between a lower and upper limit with a specific degree of certainty
- For a given sample size, if you want **more confidence** that your interval will be correct, you will have a wider interval and therefore, a **less precise** estimate
- The most commonly used level of certainty is **95%**

*Example: Imagine you're estimating the average weight gain in infants during their first year. By calculating a confidence interval around this estimate, you provide a range within which the true average weight gain likely falls, based on your sample*



# Correlation vs Regression

	Parametric	Numerical (non-parametric) Ranks, Scores	Binomial (2 X 2)
Association between 2 variables	Pearson correlation	Spearman correlation	
Predict value from another variable	Simple linear (non-linear) regression	Non-parametric regression	Simple logistic regression
Predict value from several variable	Multiple linear (non-linear) regression		Multiple logistic regression

# Hypothesis Testing

---

- A hypothesis = A tentative explanation
  - We seek to prove or disprove the explanation
- Stated as a **pair of statements**
  - The Null Hypothesis ( $H_0$ )
    - A hypothesis which the researcher tries to disprove, reject, or nullify
    - True until evidence indicates otherwise
    - If you can conclude that  $H_0$  is false (reject  $H_0$ ), then the  $H_1$  must be true
  - The Alternative Hypothesis ( $H_1$ )
    - Represents the conclusion reached by rejecting  $H_0$
    - We reject  $H_0$  if the evidence from the sample indicates that  $H_0$  is unlikely to be true



# Error Types



## Type I Error

- You commit a Type I Error if you **reject a true null hypothesis** -  $H_0$
- Alpha ( $\alpha$ ) refers to:
  - The risk, or probability, of a type I error occurring
  - Is also known as “level of significance” of the statistical test
  - **You control  $\alpha$**  by deciding the risk you are willing to tolerate of a type I error
  - **You specify  $\alpha$  before** performing the hypothesis test
  - The most common  $\alpha$  values are 0.01 and 0.05

## Type II Error

- You commit a Type II Error if you **do not reject a false null hypothesis**
- Beta ( $\beta$ ) refers to:
  - The risk, or probability, of a type II error occurring
  - Unlike the type I error, the type II error is **not directly established by you**



# Error Types - Examples



## Type I Error

- Imagine you're conducting a study to test a new medication's effectiveness in reducing fever in children.
- You set your significance level at 0.05.
- **A Type I error would be if you conclude that the medication is effective (reject the null hypothesis) when, in reality, it doesn't actually reduce fever any better than a placebo (null hypothesis is true).**


## Type II Error

- Continuing with the medication study, a **Type II error would occur if you conclude that the new medication is not effective (fail to reject the null hypothesis) when, in fact, it does reduce fever in children better than a placebo (null hypothesis is false).**

- Type I Error is like a green light (go) when you should actually stop. It's a false positive, giving you the wrong signal.
- Type II Error is like a red light (stop) when you should actually go. It's a missed opportunity because you didn't see the true signal.

# Hypothesis Testing

## Probabilities of Type I and Type II Errors



STATISTICAL DECISION (Investigator's Conclusion)	ACTUAL SITUATION	
	$H_0$ IS TRUE	$H_0$ IS FALSE
REJECT $H_0$	<b>TYPE I ERROR</b> $= \alpha$  (FALSE POSITIVE STUDY)	<b>CORRECT DECISION</b> $= 1 - \beta$ (POWER)  (TRUE POSITIVE STUDY)
DO NOT REJECT $H_0$	<b>CORRECT DECISION</b> $= 1 - \alpha$ (CONFIDENCE) (TRUE NEGATIVE STUDY)	<b>TYPE II ERROR</b> $= \beta$  (FALSE NEGATIVE STUDY)

# Hypothesis Testing: Correct & Erroneous Conclusions

## Type I Error

Erroneously concluding  $H_0$  to be false

Rejecting  $H_0$  when it is true

False positive study

## Type II Error

Erroneously concluding  $H_0$  to be true

Accepting  $H_0$  when it is false

False negative study

STATISTICAL DECISION (Investigator's Conclusion)	ACTUAL SITUATION	
	$H_0$ IS TRUE	$H_0$ IS FALSE
REJECT THE $H_0$	TYPE I ERROR = $\alpha$ (FALSE POSITIVE STUDY)	CORRECT DECISION = $1 - \beta$ (POWER) (TRUE POSITIVE STUDY)
DO NOT REJECT THE $H_0$	CORRECT DECISION = $1 - \alpha$ (CONFIDENCE) (TRUE NEGATIVE STUDY)	TYPE II ERROR = $\beta$ (FALSE NEGATIVE STUDY)

## $\alpha$ level

- The chance (probability) of rejecting  $H_0$  when it is true is  $\alpha$  level
- **The chance of Type I error is  $\alpha$  level**
- The chance of false positive study is  $\alpha$  level

## $\beta$ level


- The chance (probability) of accepting  $H_0$  when it is false is  $\beta$  level
- **The chance of Type II error is  $\beta$  level**
- The chance of false negative study is  $\beta$  level



# Sample Size

## Effect size

The smaller the effect size, the larger the sample size required





# The p-Value

---

- The actual risk of having a **type I error**
- AKA the “**observed**” level of significance
- Represents the chance of detecting a difference (inequality) in the parameters by chance when in fact there is no difference at all
- There is not a firm division between what scientists consider true and not true, but traditionally a **p-value of 0.05 or less** has been accepted as evidence of actual difference
- If  $p$  were 0.05 this means there is one chance in 20 that you could detect a difference (rejected  $H_0$ ) by pure chance when in reality there was no real difference ( $H_0$  is true)

**\*\*  $\alpha$  is set by investigators \*\***

**\*\* p-value is calculated \*\***



# Hypothesis Testing

- Significance tests are carried out on the assumption that  $H_0$  is true
- An  $\alpha$  level is set = probability of rejecting a null hypothesis when it is true.
  - False positive study
- This  $\alpha$  level is same as **p-value** of significance.
  - Usually the  $\alpha$  level is set at 0.05 (5%).
- When  $H_0$  is rejected with a p-value of  $<0.05$ , we can conclude that the rejection is unlikely due to chance alone ( $<5\%$ ).

The smaller the set p-value ( $\alpha$  level); the larger the sample size required



# Power

- **Power** = Probability of correctly identifying the difference between the two groups in study sample when one genuinely exists in population from which the samples are drawn.
  - Probability of (true) positive study
- Power is  $1-\beta$ 
  - $\beta$  is the probability of Type II error
- The sample size depends upon the power of the study.



The higher the power ( $1-\beta$ ), the larger the sample size required, and the lower the probability of Type II error

# Common Statistical Tests



<b>Data</b>	<b>Numerical (parametric)</b>	<b>Numerical (non-parametric) Ranks, Scores</b>	<b>Binomial (2 X 2)</b>
<b>Describe one group</b>	<b>Mean with Standard deviation</b>	<b>Median with Inter quartile range</b>	<b>Proportion or %</b>
<b>Compare two unpaired groups</b>	<b>Unpaired t-test</b>	<b>Mann-Whitney Test</b>	<b>Chi-square (Fisher's <math>\leq 5</math>)</b>
<b>Compare two paired groups</b>	<b>Paired t-test</b>	<b>Wilcoxon test</b>	<b>McNemar's test</b>
<b>Compare <math>\geq 3</math> unmatched groups</b>	<b>One-way ANOVA</b>	<b>Kruskal-Wallis test</b>	<b>Chi-square</b>
<b>Compare <math>\geq 3</math> matched groups</b>	<b>Repeated-measures ANOVA</b>	<b>Friedman test</b>	
<b>Association between 2 variables</b>	<b>Pearson correlation</b>	<b>Spearman correlation</b>	
<b>Predict value from another variable</b>	<b>Simple linear (non-linear) regression</b>	<b>Non-parametric regression</b>	<b>Simple logistic regression</b>
<b>Predict value from several variable</b>	<b>Multiple linear (non-linear) regression</b>		<b>Multiple logistic regression</b>



# Chi-square vs Fisher's

- Fisher's exact test is more accurate
  - Difficult to calculate manually for a large data
  - If the data points are  $<6$  ( $\leq 5$ ) in any cell (of 2X2 Table) **always use Fisher's**
- Chi-square test
  - If the data points are  $>5$  (results will be same as Fisher's test)
  - **For comparing 3 or more groups use Chi-square**

# T-test vs ANOVA

- T-test is used to compare the means of TWO groups
- **Paired t-test** is used when the data is **matched**
  - eg: pre and post data
- ANOVA is to compare the means of **THREE or more groups**
  - ANOVA = analysis of variance
- Both are used for **parametric data only**
  - Parametric = normally distributed

# Data Analysis



# Validity

EBM/  
Statistics

## Internal Validity

- Accuracy of study's conclusion
- Needed to determine the causal relations among variables

Clinical  
Application

## External validity

- How well the study represents the "real world"
- Generalizability
- Applicability



# Accuracy and Precision

## Accuracy (Validity)

- The closeness of a measurement to the true value of the quantity that is measured.
- Affected by **systematic errors**

## Precision (Repeatability; reliability)


- The closeness of agreement of two or more measurements of the same quantity.
- Affected by **random errors**

● True value;

● Measured value


A

Accurate  
and  
precise




B

Precise  
but not  
accurate




C

Accurate but not precise



D

Neither accurate nor precise





## Table. Validity Hierarchy

	Study Design	Strengths	Weaknesses
↑ Internal Validity	Randomized controlled trials	<ul style="list-style-type: none"><li>• High internal validity</li><li>• Reduced risk of confounding variables</li></ul>	<ul style="list-style-type: none"><li>• Reduced external validity</li><li>• Expensive, time-consuming</li></ul>
	Cohort studies	<ul style="list-style-type: none"><li>• Useful for sequential events</li><li>• Can study multiple outcomes</li><li>• <i>Retrospective</i>: less expensive</li></ul>	<ul style="list-style-type: none"><li>• Requires large sample size</li><li>• Risk of confounding variables</li><li>• Difficult to study rare outcomes</li><li>• <i>Prospective</i>: Expensive</li></ul>
	Case-control studies	<ul style="list-style-type: none"><li>• Useful for rare outcomes</li><li>• Can study several exposures</li><li>• Inexpensive</li></ul>	<ul style="list-style-type: none"><li>• Risk of confounding variables</li></ul>
	Cross-sectional studies	<ul style="list-style-type: none"><li>• Can study multiple outcomes and exposures</li></ul>	<ul style="list-style-type: none"><li>• Cannot infer causality</li><li>• Risk of confounding variables</li><li>• Less useful for rare exposures or outcomes</li></ul>
	Case studies	<ul style="list-style-type: none"><li>• Useful for rare outcomes</li><li>• Convenient, inexpensive</li></ul>	<ul style="list-style-type: none"><li>• Risk of confounding variables</li><li>• Lack of a comparison group</li><li>• Cannot infer causality</li></ul>

# Reliability

---

## *Test-retest reliability:*

- Assesses whether an instrument or test yields the **same results each time it is used** with the same study sample under the same study conditions
- One way to determine whether an instrument or test is reliable or consistent is to administer it with the **same subject or sample more than once**

## *Internal consistency reliability:*

- A measure of the consistency of the items within a test.

## *Inter-rater reliability:*

- The degree to which two raters independently score an observation similarly.



# Study of Any Intervention

---

- Random Error = Deviation from the underlying truth **by chance**
- Bias = **Systematic** deviation from underlying truth
  - Definition of Bias:
    - “Any **systematic error** in the design, conduct or analysis of a study that results in a mistaken estimate of an exposure’s effect on the risk of disease.”



# Bias



- Major issue in epidemiologic research studies
- Can lead to inferences that systematically deviate from truth

# Common Types of Bias

---

- **Surveillance bias:** Population being monitored more closely or more frequently than the general population
- **Selection bias:** Two primary varieties:
  1. Systematic differences in the characteristics between individuals selected for a study compared with those not selected for the study
  2. Systematic differences in the selection of cases and controls or exposed and unexposed individuals
- **Misclassification bias:** Misclassifying individuals into diseased or non-diseased groups or into exposed and unexposed groups



# Ways to Decrease Bias

(During Design, Before Completion, and After Completion)





# (During Selection of Control Group) Minimizing Selection Bias

STRATEGY	COMMENT
<i>Restriction or Specification</i>	Limits the range of characteristics of the patients in the study, decreases sample size, heterogeneity and generalizability (External Validity)
<i>Matching</i>	For each patient in the study group, select one or more patients with the same characteristics for a comparison group
<i>Adjustment</i>	Mathematical corrections to create an equal weight for dissimilar characteristics
<i>Stratification</i>	Compare outcomes from subgroups of each group with similar characteristics (i.e. age by decades)
<i>Randomization</i>	Randomization of the study population and controls

Ref: Clinical Epidemiology The Essentials. 3<sup>rd</sup> Ed. Fletcher et al. 1996, p 129.



# (Before Study Completion) Ways to Decrease Bias

STRATEGY	BENEFITS	TRADE-OFF
<b>Limitations for participation (Exclusion Criteria)</b>	<ul style="list-style-type: none"> <li>•By restricting the heterogeneity of the group, we reduce the opportunity for differences in outcome that aren't due to the treatment itself</li> <li>•<b>Improves INTERNAL VALIDITY</b></li> </ul>	Makes generalization of the results more precise but <b>limits EXTERNAL VALIDITY/ GENERALIZABILITY</b> to a smaller portion of the population
<b>Use of a Control/ Comparison Group</b>	Minimizes the ‘Hawthorne effect’ <i>By virtue of being in a study, the patient’s behavior changes and has a better prognosis</i>	Still may have a “placebo effect” unless placebo given to control group <i>Giving a pill with an expected/potential result can provide effect even if the pill is inert</i>



# Confounding

---

- One of several **threats to internal validity** of a research study
- Confounding is defined as:
  - A possible source of bias in studies in which an unmeasured third variable (the confounder) is related to the exposure of interest (although not causally) and causally related to the outcome of interest



# (After Study Completion) Dealing With Confounding

## Two ways

### Stratification

- Subdividing subjects by levels of a potential KNOWN confounding variable
- Testing for the association of exposure with outcome within each stratum
- **Disadvantages:**
  - May not be feasible to handle multiple confounders
  - As the number of strata increase, sample size within each stratum decreases, reducing statistical power
  - May not adequately control for confounding

### Multivariate Techniques

- Permit understanding of how much variability in an outcome is accounted for by a confounder
- Permit researchers to control for more factors than stratification
- **Disadvantages:**
  - Require readers to understand how to interpret the meaning of adjusted odds ratios and regression coefficients as well as how statistical significance was determined

# Randomization

## What?


- Participation in a study arm by **chance**, not by choice
- Equal & fair chance of getting intervention or control

## Goals

- **Produce comparable groups** in terms of general participant characteristics (known and unknown confounders)
- The two groups will be similar at the baseline
- **Avoids selection bias**

## How?

- **Simple randomization:** repeated fair coin-tossing; good for large sample
- **Block randomization:** subjects randomized in a block (of 6 or 8) to prevent uneven allotment in a small sample
- **Stratified randomization:** randomize to groups according to covariates (like age groups under and over 12 years)



# Blinding & Allocation Concealment

## Blinding/ Masking

- **Types of blinding**
  - Single-blind (subject or care giver)
  - Double-blind (subject and care giver)
  - Triple-blind (subject, care giver and data analyzer)
- **Open trial:** unblind or unmasked study
- **Benefit:** Removes the bias
  - Placebo effect
  - Observer bias (change in behavior due to the awareness of being observed; Hawthorne Effect)
  - Experimentor bias

## Allocation Concealment

- Not same as “blinding”
- The subject and the investigator do not know the allocation of the group until randomization
  - After allocation it may or may not be blinded

## Potential Bias

## Strategy Against

### Sampling Bias

- Target population

### Selection Bias

- Randomization

### Placebo Effect

- Placebos
- Blinding participants

### Cointerventions

- Blinding Providers
- Treatment protocols

### Assessment Bias

- Blinding Providers

### Follow-up

- Ensuring completeness



# Reading & Interpreting Results (EBM)





# The 5 Steps of Evidence-Based Medicine



It all starts with asking the right question



Step 1

**Ask**  
a clinical  
question

Step 2

**Acquire**  
the best  
evidence

Step 3

**Appraise**  
the  
evidence

Step 4

**Apply**  
the  
evidence

Step 5

**Assess**  
your  
performance

*The five steps of evidence-based medicine include the 5 As: ask, acquire, appraise, apply, and assess.*



**Nicklaus  
Children's  
Hospital**

# P.I.C.O. Question – 4 Components

---

- **P = Patient/Population and Problem:** Ask “how would I describe a group of patients similar to mine?” Balance precision with brevity, be specific
- **I = Intervention:** Ask “which main intervention am I considering?” (cause, prognostic factor, treatment, etc..)
- **C = Comparison/Control:** Ask “which is the main alternative to compare with the intervention?” again, be specific
- **O = Outcome of interest:** Ask “what can I hope to accomplish?” or “what could this exposure really affect?” again, be specific.



# PICO Question

Table 1. Example of the PICO Process to Identify a Research Question

P	Patient or Population	Newborns
I	Intervention or Indicator	Newborn screen for congenital hypothyroidism
C	Comparison	Serum TSH measurement
O	Outcome	Diagnosis of congenital hypothyroidism or the "accuracy of the test"

Table 3. Sample Search Terms

	Key Concepts	Search Term
P	Newborns	Newborn or infant
I	Newborn screen for congenital hypothyroidism	Newborn screen for congenital hypothyroidism or congenital hypothyroidism diagnosis
C	Compared with TSH	
O	Accuracy of test	Accuracy or diagnosis

# Incidence vs Prevalence

## Incidence

- # of new events or cases of disease /population at risk during a specified time interval
- Provides an estimate of the probability (risk) that an individual will develop a disease during a specified period of time

## Prevalence


- Total # of existing cases / the total population (at a given point in time)
  - Quantifies the **proportion of individuals in a population** who have the disease at a specific instant
- Provides an estimate of the probability (risk) that an individual will be ill at a point in time



# Studies and Clinical Questions

---

- Four possible Domains:



# Therapy Studies

---

- Best is **RCT**, followed by Cohort
- Subjects randomized to:
  - New Treatment (A) or Old Treatment (B)
  - New Treatment or Placebo
- Outcome is measured (Improvement)

You Calculate a NNT

$$\text{NNT} = 1/\text{ARR}$$



# Relative Risk (RR); Absolute Risk Reduction (ARR); Relative Risk Reduction (RRR); & Number Needed to Treat (NNT)

- In an experiment the mortality fell to 30% with a new treatment  $[P(E)]$  from 40% in control group  $[P(C)]$ .
  - What is the relative risk (RR) of mortality with the new treatment?
  - What is the absolute risk reduction (ARR) of mortality with the new treatment?
  - What is the relative risk reduction (RRR) of mortality with the new treatment?
  - How many patients need to be treated with the new medication to avoid one death?



# Relative Risk (RR)

- **Relative risk** = the ratio of the risk of an event in experimental group to the risk of the same event in control (or other) group.

$$RR = P(E) / P(C)$$

- From the previous example:
  - $P(E) = 0.3$  (30%)
  - $P(C) = 0.4$  (40%)
  - $RR = P(E)/P(C) = 0.3/0.4 = 0.75$  (75%)
  - The relative risk of mortality with the new treatment is 0.75
    - The mortality in the Rx group is 75% of that in control group



# Absolute Risk Reduction (ARR)

- Absolute risk reduction (ARR) or called risk decreased (RD) = the difference in the risks of an event in two groups.

$$ARR = P(C) - P(E)$$

- In the example given:
  - $P(E) = 0.3$
  - $P(C) = 0.4$
  - $ARR = (0.4 - 0.3) = 0.1$  (10%)
  - Mortality risk is 10% less with the new Rx compared to that in control group


# Relative Risk Reduction (RRR)

- Relative risk reduction (RRR) = the ratio of absolute risk reduction (ARR) to the risk in control group.

$$RRR = (P(C) - P(E))/P(C) = (ARR)/P(C)$$

- In the example given:
  - $P(E) = 0.3$
  - $P(C) = 0.4$
  - $RRR = (0.4 - 0.3)/0.4 = 0.1/0.4 = 0.25$  (25%)
  - Mortality risk is reduced by 25% with the new Rx compared to that in control group

# Number Needed to Treat (NNT)



$$\text{NNT} = 1/\text{ARR}$$

- In the example given:
  - $P(E) = 0.3$
  - $P(C) = 0.4$
  - $\text{ARR} = (0.4 - 0.3) = 0.1$
  - $\text{NNT} = 1/\text{ARR} = 1/0.1 = 10$
  - We need to treat **10** patients with the new Rx to avoid one death

# Intention-to-Treat Principle

- **GOAL:** Preserves the randomization of unknown confounders
- Include all patients in the group they have randomized to, irrespective of the treatment received or not
- Include the subjects in the original group for analysis even if
  - They have stopped receiving the study intervention
  - They have crossed over to the counter intervention
  - They were lost to follow-up
  - Died
  - Left the study

# Harm/ Association Studies

---

- RCT unethical
- Cohort is next best
- Outcome is measured (Harm)

You calculate a NNH

$$\text{NNH} = 1/\text{ARI}$$



# Association is Different from Causation

---

- Five criteria must be fulfilled to prove causation:
  1. Is it clear that the **exposure preceded the onset of the outcome**? – Looks at exclusion criteria
  2. Is there a **dose-response** gradient?
    - e.g. Smoking and lung cancer
  3. Is there any positive evidence from a **de-challenge / re-challenge** study?
  4. Is the association **consistent** from study to study?
  5. Does the association make **biological sense**? - Pathophysiology

# Case-Control Studies

## Odds Ratio (Relative Odds)

Adverse Outcome

	<b>Present</b>	<b>Absent</b>	<b>Totals</b>
<b>Exposure Yes</b>	a	b	<b>a+b</b>
<b>Exposure No</b>	c	d	<b>c+d</b>
<b>Totals</b>	<b>a+c</b>	<b>b+d</b>	<b>a+b+c+d</b>

$$OR = (a/c)/(b/d) = ad/bc$$

# What is Risk?

---

- Risk is the probability of an event!
- In statistical terms: Risk is  $P(e)$

In statistics, RISK doesn't mean harmful events!





# Probability vs Odds

- $P = \frac{\text{Odds}}{1 + \text{Odds}}$
- $\text{Odds} = \frac{P}{1 - P}$

PROBABILITY	ODDS
$P(e) = e/n = \text{events} / (\text{events} + \text{non-events})$	Odds = events/ non-events
$P = \# \text{ of events} / \text{Total possible events}$	
EXAMPLE	EXAMPLE
<i>In deck of cards: P(spade)</i>	<i>In deck of cards: Odds(spade)</i>
<ul style="list-style-type: none"> <li>• 13 events (spades in the deck)</li> <li>• 39 non-events (52-13, non-spade cards)</li> <li>• <math>P(\text{spade}) = 13 / (13+39) = 13/52 = 1/4</math></li> </ul>	<ul style="list-style-type: none"> <li>• 13 events (spades in the deck)</li> <li>• 39 non-events (52-13, non-spade cards)</li> <li>• Odds for spade = <math>13/39 = 1/3</math></li> </ul>
<i>Probability of picking a spade from a deck of cards is 1 in 4</i>	<i>The odds of picking a spade from a deck of cards is 1 in 3</i>



## Pearl to Remember

**Probability is always smaller than odds. P vs O**

Hence, the denominator is larger to calculate probability from odds (1+odds) compared to odds from probability (1-probability)

# Odds Ratio (OR)

---

- Ratio of Odds
- The odds of a case patient being exposed divided by the odds of a control patient being exposed
- Calculated in Case-Control studies
- Proportion exposed in a diseased vs. non-diseased patient sample
- $OR > 1$  represents an increased risk or association
- Describes the relative harm of an exposure independent of disease prevalence
- When the prevalence of the outcome of interest is rare in the population from which the sample was drawn (often the reason for using a case-control study), the OR closely approximates the RR



# Diagnostic Test Studies

- All subjects receive the new test and the “gold standard”  
e.g. Rapid Strep and throat culture
- 4 possibilities

## By Gold Standard

	Patients with disease	Patients without disease
Test is positive	<b>a</b> true positive	<b>b</b> false positive
Test is negative	<b>c</b> false negative	<b>d</b> true negative

# Evaluating the Evidence – Diagnostic Test

Construct the 2x2 table

	Patients with disease	Patients without disease
Test is positive	a true positive	b false positive
Test is negative	c false negative	d true negative

Sensitivity =  $a / a+c = P(+/D) = P(\text{TP among diseased}) = \text{TP} / (\text{TP} + \text{FN})$   
Specificity =  $d / b+d = P(-/\bar{D}) = P(\text{TN among non diseased}) = \text{TN} / (\text{FP} + \text{TN})$

PPV =  $a / a+b = P(D/+ ) = P(\text{TP among all Positives}) = \text{TP} / (\text{TP} + \text{FP})$   
NPV =  $d / c+d = P(\bar{D}/- ) = P(\text{TN among all Negatives}) = \text{TN} / (\text{FN} + \text{TN})$

# Sensitivity & Specificity of a Test

## Sensitivity

- Ability of a test to recognize correctly persons who ***have a disease*** or condition
- Proportion of patients who have a disorder in whom the results of the test are *positive*

**PID**

(Positive in Disease)

## Specificity

- Ability of a test to recognize correctly persons who ***do not have a disease*** or condition
- Proportion of patients who do not have a disorder in whom the test result is *negative*

**NIH**

(Negative in Health)

# SpPin & SnNout



- **SpPin** = Result of a test with high **Sp**ecificity, when **P**ositive, rules **in** the diagnosis
- **SnNout** = Result of a test with high **Sen**sitivity, when **N**egative, rules **out** the diagnosis

**Discriminant ability of a test =  
(sensitivity+specificity)/2**



# Predictive Values of a Test

## PPV

- Proportion of patients **testing positive** who actually have the disease or condition in question

## NPV

- Proportion of patients **testing negative** who actually *do not* have the condition in question

# IMPORTANT



- Sensitivity and specificity are properties **intrinsic to a test** and are **not** affected by the prevalence of a particular disease or condition
- The predictive values of a diagnostic test are influenced greatly by prevalence. **The higher the disease prevalence, the higher the PPV.** e.g. The rapid flu test has a higher PPV during the flu season (time of high prevalence)





# Pretest Probability Post-test Probability

## Baye's Theorem

LR calculator: <http://getthediagnosis.org/calculator.htm>

- Varies by: Physician experience, season, geography, prevalence, and the history and physical findings
- Clinician's best estimate of the probability of a specific disease **before** diagnostic testing
- Generally has a large impact on the diagnostic process

**Pre-test Probability (X)**

**Likelihood Ratio  
LR(+) or LR(-)**

- Links Sensitivity and Specificity
- Indicates by how much a given diagnostic test result will raise or lower the pretest probability of the target disorder

**Post-test Odds:  $Z = Y \times LR$**

**Post-test probability =  $Z/(Z+1)$**

- Depends on the magnitude of LR
- Is the clinician's best estimate of the probability of a specific disease **after** diagnostic testing

**Post-Test Probability**

**Pre-test Odds:  $Y = X/(100-X)$**

# Likelihood Ratios

## LR(+)

- Probability of person WITH disease having positive test/probability of person WITHOUT disease having a positive test
- $P(TP)/P(FP)$
- $LR(+) = \text{Sens}/(1-\text{spec})$
- Corresponds to clinically “ruling in disease”


## LR(-)

- Probability of person WITH disease having negative test/probability of person WITHOUT disease having negative test
- $P(FN)/P(TN)$
- $LR(-) = (1-\text{sens})/\text{spec}$
- Corresponds to clinically “ruling out disease”

Indicate by how much a given diagnostic test result will raise or lower the pretest probability of the target disorder

- $LR = 1 \rightarrow$  Post-test probability = Pre-test probability
- $LR > 1 \rightarrow$  increases the probability that the target disorder is present
- $LR < 1 \rightarrow$  decreases the probability that the target disorder is present

# Guide to the Significance of LRs



LR	Interpretation
> 10	Large and often conclusive increase in the likelihood of disease
5 - 10	Moderate increase in the likelihood of disease
2 - 5	Small increase in the likelihood of disease
1 - 2	Minimal increase in the likelihood of disease
1	No change in the likelihood of disease
0.5 - 1.0	Minimal decrease in the likelihood of disease
0.2 - 0.5	Small decrease in the likelihood of disease
0.1 - 0.2	Moderate decrease in the likelihood of disease
< 0.1	Large and often conclusive decrease in the likelihood of disease

- LR > 10 or < 0.1 generate large and often conclusive changes from pre-test to post-test probability
- LR = 5 - 10 or 0.1 - 0.2 generate moderate shifts pre-test to post-test
- LR = 2 - 5 or 0.5 - 0.2 generate small, but sometimes important changes in probability
- LR = 1 - 2 or 0.5 - 1 are rarely important shifts




# Prognosis Studies

---

- RCTs are unethical and not feasible
- Cohort or Case-Control
- How likely are the outcomes over time?
  - Three ways of reporting it:
    - % Survival at a particular point in time (1 year or 5 year survival)
    - Median Survival (Length of F/U by which 50% of the study patients have died)
    - Survival Curves/ Kaplan-Meier Curve (% of study population at each point in time that is free of the specified outcome)





**Median Survival:**

- Group 1: 23 years
- Group 2: 8 Years

**5-Year Survival:**

- Group 1: 100%
- Group 2: 69%



Nicklaus Children's Hospital



Nicklaus Children's Hospital


# Type of Question and Study Design



Type of Question	Suggested best type of Study
Therapy	RCT > cohort > case control > case series
Diagnosis	Prospective, blind comparison to a gold standard
Etiology/Harm	RCT > cohort > case control > case series
Prognosis	Cohort study > case control > case series
Prevention	RCT > cohort study > case control > case series
Clinical Exam	Prospective, blind comparison to gold standard
Cost	Economic analysis




# Research & Study Design



# Studies in Medical Literature

- **Two** main categories:



## Observational

- Studies in which subjects are observed (No Intervention)



## Experimental

- Studies in which the effect of an intervention is observed





# Observational Studies


Case Reports/ Case Series

Cross Sectional

Case-Control

Cohort

# Observational Studies



## CASE REPORTS/ CASE SERIES

- Observations, **small number** of patients
- **Simplest** design/ Descriptive
- Lead to hypothesis
- Over short period of time
- No controls
- **Easy** to write
- Subject to many biases
- **WEAKEST FORM OF EVIDENCE**

## Observational Studies

Case Reports/ Case Series

Cross Sectional

Case-Control

Cohort



## CROSS SECTIONAL

- AKA Surveys/ Epidemiologic/ Prevalence
- Short time (snapshot in time)
- What is happening now?
- Quick/ inexpensive

# Observational Studies

## Observational Studies

Case Reports/ Case Series

Cross Sectional

Case-Control

Cohort



## CASE-CONTROL


- **Retrospective** (“what happened?”)
- Enrolls subjects **with disease/ outcome** (cases) and no disease (control) and ask about exposure
- Matching needed for controls
- Useful for **rare diseases** & **diseases that take long time** to develop
- Quickest/ cheap
- Large biases
- No estimate of disease incidence or prevalence
- Only allows to study **one outcome at a time**
- **You Calculate O.R.** (You do not have the whole population at Risk)



## COHORT

- **Prospective** (“what will happen?”)
- Enrolls subjects **before the disease** and follow them forward looking for outcomes
- Estimates incidence or natural history of disease
- Useful to prove association between disease and exposure
- Cannot be used to prove causation
- Can be costly if long F/U (subject to patient attrition)
- May allow **multiple outcomes** assessment (clinical, economic, QOL, ..)

# Prospective Cohort Study




## Steps:

- Select a sample of the population
- Measure predictor variables (risk factor)
- Follow-up the cohort
- Measure outcome variables (disease)

# Cohort studies: marching towards outcomes (Prospective)


Looking forward in  
the past =  
Retrospective Cohort



*Lancet* 2002; 359: 341-45

The defining characteristic of all cohort studies is that they track people forward in time **from exposure to outcome**. Data collection may be prospective or retrospective.  
Ex. Contraceptives and DVT.

# Observational Studies



## Longitudinal Studies

“Notion of Time”


Table. Summary of Designs

Study Design	Definition	Strengths	Weaknesses
Cross-Sectional	Single data collection point	<ul style="list-style-type: none"> <li>• Quick</li> <li>• Inexpensive</li> <li>• Establishes prevalence</li> <li>• Suggests future research directions</li> </ul>	<ul style="list-style-type: none"> <li>• Difficult to determine causality</li> <li>• Possible spurious associations</li> </ul>
Longitudinal Prospective Retrospective	Multiple data collection points occur over time	<ul style="list-style-type: none"> <li>• Can determine causality</li> <li>• Can monitor trends</li> <li>• Less concerned with spuriousness</li> </ul>	<ul style="list-style-type: none"> <li>• Time-consuming</li> <li>• Expensive</li> </ul>



# Studies in Medical Literature

- **Two** main categories:



## Observational

- Studies in which subjects are observed (No Intervention)



## Experimental

- Studies in which the effect of an intervention is observed

# Experimental Studies

## AKA “Clinical Trials”

(easy to identify, explicitly stated in the abstract, Expensive)

## Experimental Studies



## Controlled Trials

## Uncontrolled Trials

## Self-Controls

- Subject to bias (Hawthorne effect)
- Can do crossover study (with washout period in between)

## Independent Concurrent Controls

## External Controls


- Uses the results of another investigator’s research as a comparison
- Historical controls can also be used: for disease with no cures yet

## RCT

- Considered the “gold standard”
- Double or single blind
- **The epitome of all research designs**
- Provides the strongest evidence of concluding causation
- Best insurance that results are due to the intervention


## Non-Randomized

- Opened to biases






# Classification of Types of Clinical Research



# Hierarchy of Research Design

Best



Systematic Reviews  
and Meta-analyses

Randomized  
Controlled Double  
Blind Studies

Cohort Studies

Case Control Studies

Case Series

Case Reports

Ideas, Editorials, Opinions

Animal research

In vitro ('test tube') research

## Advantages and Limitations

- Pool results from **multiple** studies
- Findings offer a compilation of evidence (Greater power than an individual study)
- **Meta-analysis of multiple RCTs is the best**
- Meta-analysis = Systematic Review + analysis of results of multiple studies.
- The most significant limitation of both systematic reviews and meta-analyses is commonly described as “garbage in, garbage out.”

Worst



# Phases of Clinical Trials



# Phases of Clinical Trials

Phase	Primary Goal	Dose	Patient Monitor	Typical No. of participants	Notes
<b>Preclinical</b>	<ul style="list-style-type: none"> <li>Testing in <b>non-human</b> subjects</li> <li>Gather efficacy, toxicity and pharmacokinetic info</li> </ul>	Unrestricted	Graduate level researcher (PhD)	N/A (In vitro and in vivo only)	
<b>Filing &amp; Approval of IND* (Investigational New Drug) Application</b>					
<b>Phase 0</b>	<ul style="list-style-type: none"> <li>Pharmacodynamics and Pharmacokinetics</li> <li>Particularly oral bioavailability and half-life of the drug</li> </ul>	Very small, subtherapeutic	Clinical researcher	10 people	Often skipped for phase I
<b>Phase I</b>	Testing of drug on <b>healthy volunteers</b> for dose ranging	Often subtherapeutic, but with ascending doses	Clinical researcher	20-100	<ul style="list-style-type: none"> <li>Determine effectiveness</li> <li>Evaluate Safety</li> </ul>
<b>Phase II</b>	Testing of drug on <b>patients</b> to assess efficacy and safety	therapeutic dose	Clinical researcher	100-300	<ul style="list-style-type: none"> <li>Determines efficacy</li> <li>At this point, the drug is not presumed to have any therapeutic effect whatsoever</li> </ul>

\*IND – Permission to conduct the Clinical Trial

# Phases of Clinical Trials


Phase	Primary Goal	Dose	Patient Monitor	Typical No. of participants	Notes
Phase III	<ul style="list-style-type: none"> <li>Testing of drug on <b>patients</b></li> <li>Assess efficacy, effectiveness and safety</li> </ul>	Therapeutic dose	clinical researcher and personal physician	1000-2000	<ul style="list-style-type: none"> <li>Determines a drug's therapeutic effect</li> <li>At this point, the drug is presumed to have some effect</li> <li>Confirm effectiveness</li> <li>Monitor side effects</li> <li>Compare it to standard treatment</li> <li>Collect info to use the drug safely</li> </ul>
<b>Filing and Approval of NDA* (New Drug Application) to FDA to Approve the Drug for Marketing</b>					
Phase IV	<b>Postmarketing</b> Surveillance – watching drug use in the public	Therapeutic dose	personal physician	Anyone seeking treatment from their physician	<ul style="list-style-type: none"> <li>Watch long-term effects &amp; side effects</li> <li>Info on drug effect in various populations</li> </ul>
Phase V	Translational research	No dosing	None	All reported use	Research on data collected


\*NDA – Permission to Market the New Drug



<http://www.nlm.nih.gov/services/ctphases.html>  
[http://en.wikipedia.org/wiki/Phases\\_of\\_clinical\\_research](http://en.wikipedia.org/wiki/Phases_of_clinical_research)







**The More I Think  
The More Confused I Get**





Спасибо Gracias شکر Obrigado Спасибо Dank U  
Grazie Ευχαριστώ Danke  
Merci Thank You Ngiyabonga Dank U  
Dziękuję Danke Diolch Ngiyabonga Tack Thank You  
Danke Grazie Thank You  
Merci Dank U Terima Kasih Diolch  
Dziękuję Diolch Gracias Merci Dank U Diolch  
Danke Grazie Tack Tack Ευχαριστώ

